The FCF Healthcare & Life Sciences Venture Capital Monitor – Europe is a monthly overview of financing trends in the venture capital sector, with a focus on European healthcare and life sciences companies.
Total Healthcare & Life Sciences funding reached EUR 7,843m (+8% vs. 2025)
Biotech/Pharma received 35% of the total investment volume (EUR 2,761m), with oncology being the leading indication (30%)
In August, Vaderis Therapeutics (Switzerland) secured the highest transaction volume with EUR 133m, followed by Kynexis (Netherlands) with EUR 97m and Mironid (United Kingdom) with EUR 40m
GV (United States) is the most active investor (by deal volume in 2026), followed by Alphabet (United States) and CapitalG (United States)
To read the full report, click here.